Thor Medical Secures Major Supply Deal with AdvanCell

Nordic Nanovector ASA (DE:8NN) has released an update.

Thor Medical ASA has signed a strategic five-year supply agreement with AdvanCell, marking another milestone for Thor’s AlphaOne plant. The agreement is valued at approximately NOK 100 million and aims to meet the growing demand for Thorium-228 used in innovative cancer therapies. This collaboration enhances both companies’ positions in the radiopharmaceutical industry, advancing new cancer treatments globally.

For further insights into DE:8NN stock, check out TipRanks’ Stock Analysis page.